Marex Group Ltd (MRX) officer’s 16,666-share 10b5-1 stock sale detailed

Rhea-AI Filing Summary

Marex Group Ltd officer Paolo Tonucci reported open-market sales of 16,666 Ordinary Shares on July 13, 2026, at weighted-average prices between $63.645 and $65.75 per share. These trades were executed under a pre-arranged Rule 10b5-1 plan adopted on October 22, 2025. The reported position includes 220,746 shares underlying deferred bonus plan awards, each representing a contingent right to receive one ordinary share upon vesting and settlement.

Insider Trade Summary 10b5-1

Net Seller: 16,666 shares ($1,073,578)

Net Sell 3 txns

Insider Tonucci Paolo

Role See Remarks

Sold 16,666 shs ($1.07M)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	11,850	$64.2243	$761K
Sale	Ordinary Shares	4,584	$64.8496	$297K
Sale	Ordinary Shares	232	$65.7301	$15K

Holdings After Transaction: Ordinary Shares — 1,287,093 shares (Direct)

Footnotes (1)

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on October 22, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $63.645 to $64.645, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $64.65 to $65.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $65.715 to $65.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The number of ordinary shares reported herein includes 220,746 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

Key Figures

Shares Sold: 16,666 Ordinary Shares Sale Price Range: $63.645 to $65.75 per share Largest Single Lot: 11,850 Ordinary Shares +1 more

4 metrics

Shares Sold 16,666 Ordinary Shares Total Ordinary Shares sold in open-market transactions on July 13, 2026

Sale Price Range $63.645 to $65.75 per share Ranges of individual trade prices underlying reported weighted-average prices

Largest Single Lot 11,850 Ordinary Shares Largest reported sale lot on July 13, 2026 at a weighted-average price of $64.2243

Deferred Bonus Plan Awards 220,746 Ordinary Shares Shares underlying deferred bonus plan awards included in the reported share count

Key Terms

Rule 10b5-1 plan, weighted average price, deferred bonus plan awards, contingent right

4 terms

Rule 10b5-1 plan regulatory

"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

deferred bonus plan awards financial

"includes 220,746 shares underlying deferred bonus plan awards previously granted"

Deferred bonus plan awards are payments promised to employees or executives that are earned now but paid out later, often only if certain performance goals are met or the employee remains with the company. For investors, they matter because they influence management’s incentives and company expenses over time—like a delayed paycheck that encourages someone to stay and meet targets—and can affect future cash needs, reported compensation costs, and potential share dilution.

contingent right financial

"Each award represents a contingent right to receive one (1) ordinary share"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/15/2026 - 04:05 PM Accepted by SEC EDGAR 07/15/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What did Marex Group Ltd (MRX) officer Paolo Tonucci report in this Form 4?

Paolo Tonucci reported open-market sales of 16,666 Ordinary Shares of Marex Group Ltd on July 13, 2026. The filing states these transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating they were scheduled in advance rather than discretionary market-timed sales.

How many Marex Group Ltd (MRX) shares did Paolo Tonucci sell and at what prices?

Tonucci sold a total of 16,666 Ordinary Shares of Marex Group Ltd. The Form 4 reports weighted-average sale prices for the trades, with executions occurring in ranges between $63.645 and $65.75 per share, reflecting multiple individual transactions within those price bands.

Were Paolo Tonucci’s Marex Group Ltd (MRX) share sales made under a Rule 10b5-1 plan?

Yes. A footnote explains the sales were effected under a Rule 10b5-1 plan that Tonucci entered into on October 22, 2025. Such plans pre-schedule trades, so the timing of these transactions is less indicative of his short-term view on Marex Group’s stock.

What price ranges are disclosed for the Marex Group Ltd (MRX) share sales?

The filing reports weighted-average prices for each trade, with underlying individual sales occurring in ranges of $63.645–$64.645, $64.65–$65.57, and $65.715–$65.75 per share. Tonucci undertakes to provide full breakdowns of shares sold at each price upon request.

What are the 220,746 Marex Group Ltd (MRX) deferred bonus plan shares mentioned in the Form 4?

A footnote states the reported holdings include 220,746 shares underlying deferred bonus plan awards previously granted to Tonucci. Each award represents a contingent right to receive one Marex Group ordinary share when the applicable award vests and is settled.

Does the Marex Group Ltd (MRX) Form 4 show any derivative or option exercises by Paolo Tonucci?

No. The reported transactions all involve Ordinary Shares classified as non-derivative securities, each coded as an open-market sale. The filing’s summary shows no derivative exercises, gifts, or tax-withholding transactions associated with options or other derivative awards.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tonucci Paolo

(Last) (First) (Middle)

C/O MAREX GROUP LIMITED, 155 BISHOPSGATE

(Street)

LONDON UNITED KINGDOM EC2M 3TQ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Marex Group Ltd [ MRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	07/13/2026		S(1)		11,850	D	$64.2243(2)	1,287,093	D
Ordinary Shares	07/13/2026		S(1)		4,584	D	$64.8496(3)	1,282,509	D
Ordinary Shares	07/13/2026		S(1)		232	D	$65.7301(4)	1,282,277(5)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by the Reporting Person on October 22, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $63.645 to $64.645, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $64.65 to $65.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $65.715 to $65.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The number of ordinary shares reported herein includes 220,746 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

Remarks:

Chief Strategist and CEO, Capital Markets

	/s/ Scott Linsley as Attorney-in-Fact, for Paolo Tonucci	07/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)